Literature DB >> 23546765

Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

Theodosios D Filippatos1, Evangelos C Rizos, Vasilios Tsimihodimos, Irene F Gazi, Alexandros D Tselepis, Moses S Elisaf.   

Abstract

Alterations in high-density lipoprotein (HDL) subclass distribution, as well as in the activities of HDL-associated enzymes, have been associated with increased cardiovascular disease (CVD) risk. HDL subclass distribution and the activities of HDL-associated enzymes remain unknown in prediabetic patients, a condition also associated with increased CVD risk. The aim of the present study was to assess any differences in HDL subclass distribution (using polyacrylamide gel electrophoresis) and in activities of HDL-associated enzymes between prediabetic (impaired fasting glucose, IFG, n = 80) and non-prediabetic subjects (n = 105). Subjects with prediabetes had significantly increased waist circumference, blood pressure and triacylglycerol (TAG) levels compared with subjects with fasting glucose levels <100 mg/dL (all p < 0.05). The proportion of small HDL3 over HDL cholesterol (HDL-C) was significantly increased in prediabetic subjects compared with their controls (p < 0.05). The activity of the anti-atherogenic HDL-associated lipoprotein-associated phospholipase A₂ (HDL-LpPLA₂) was significantly lower in subjects with prediabetes (p < 0.05), whereas the activity of paraoxonase 1 (using both paraoxon and phenyl acetate as substrates) did not significantly differ between subjects with or without prediabetes. In a stepwise linear regression analysis, the proportion of small HDL3 over HDL-C concentration was independently associated with the presence of prediabetes and with total cholesterol and TAG concentration (positively), as well as with HDL-C levels (negatively). We also observed a trend of increased small dense low-density lipoprotein cholesterol levels in prediabetic subjects compared with their controls. Subjects with IFG exhibit increased proportion of small HDL3 particles combined with decreased activity of the anti-atherogenic HDL-LpPLA₂.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23546765     DOI: 10.1007/s11745-013-3787-1

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  50 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

Review 2.  A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

Authors:  Anastazia A Kei; Theodosios D Filippatos; Vasilios Tsimihodimos; Moses S Elisaf
Journal:  Metabolism       Date:  2012-02-02       Impact factor: 8.694

3.  PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

Authors:  A D Tselepis; C Dentan; S A Karabina; M J Chapman; E Ninio
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-10       Impact factor: 8.311

4.  Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria.

Authors:  Irene Gazi; Vasilis Tsimihodimos; Theodosios Filippatos; Eleni Bairaktari; Alexandros D Tselepis; Moses Elisaf
Journal:  Metabolism       Date:  2006-07       Impact factor: 8.694

5.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma.

Authors:  Irene Gazi; Evangelia S Lourida; Theodosios Filippatos; Vasilis Tsimihodimos; Moses Elisaf; Alexandros D Tselepis
Journal:  Clin Chem       Date:  2005-10-13       Impact factor: 8.327

6.  Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men.

Authors:  J Wang; A Stančáková; P Soininen; A J Kangas; J Paananen; J Kuusisto; M Ala-Korpela; M Laakso
Journal:  J Intern Med       Date:  2012-07-27       Impact factor: 8.989

7.  Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

Authors:  Vasilis Tsimihodimos; Sonia-Athena P Karabina; Afroditi P Tambaki; Eleni Bairaktari; John A Goudevenos; M John Chapman; Moses Elisaf; Alexandros D Tselepis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-02-01       Impact factor: 8.311

Review 8.  Economic costs of diabetes in the U.S. In 2007.

Authors: 
Journal:  Diabetes Care       Date:  2008-03       Impact factor: 19.112

Review 9.  Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity.

Authors:  Shirya Rashid; Takehiko Watanabe; Taro Sakaue; Gary F Lewis
Journal:  Clin Biochem       Date:  2003-09       Impact factor: 3.281

10.  Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes.

Authors:  Cecilia Morgantini; Andrea Natali; Beatrice Boldrini; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Ele Ferrannini; Srinivasa T Reddy
Journal:  Diabetes       Date:  2011-08-18       Impact factor: 9.461

View more
  7 in total

Review 1.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

2.  Mediterranean Diet and 10-year (2002-2012) Incidence of Diabetes and Cardiovascular Disease in Participants with Prediabetes: The ATTICA study.

Authors:  Theodosios D Filippatos; Demosthenes B Panagiotakos; Ekavi N Georgousopoulou; Evangelia Pitaraki; Georgia-Maria Kouli; Christina Chrysohoou; Dimitrios Tousoulis; Christodoulos Stefanadis; Christos Pitsavos
Journal:  Rev Diabet Stud       Date:  2017-02-10

Review 3.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 4.  Effects of glucagon-like peptide-1 receptor agonists on renal function.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Diabetes       Date:  2013-10-15

Review 5.  Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," Diabetes and Atherosclerosis.

Authors:  T D Filippatos; K Alexakis; V Mavrikaki; D P Mikhailidis
Journal:  Dig Dis Sci       Date:  2021-01-19       Impact factor: 3.199

6.  Oestradiol: any role in cardiovascular risk factors in female centenarians of Hainan?

Authors:  Qiao Zhu; Yao Yao; Chao-Xue Ning; Xiao-Ping Chen; Fu-Xin Luan; Liang Liu; Qiong Liu; Na Wang; Fu Zhang; Ya-Li Zhao
Journal:  BMC Cardiovasc Disord       Date:  2019-05-16       Impact factor: 2.298

Review 7.  Novel biomarkers for prediabetes, diabetes, and associated complications.

Authors:  Brenda Dorcely; Karin Katz; Ram Jagannathan; Stephanie S Chiang; Babajide Oluwadare; Ira J Goldberg; Michael Bergman
Journal:  Diabetes Metab Syndr Obes       Date:  2017-08-14       Impact factor: 3.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.